Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12
Aerpio Pharmaceuticals (Nasdaq: ARPO) will release its Q2 2020 financial results on August 12, 2020, before market open, followed by a conference call at 8:30 AM ET. The biopharmaceutical company focuses on developing compounds activating Tie2 for ocular diseases, ARDS related to COVID-19, and diabetic complications. Key compounds include razuprotafib for open-angle glaucoma and ARP-1536 for diabetic vascular complications. The company also has a bispecific antibody targeting VEGF and VE-PTP for age-related macular degeneration.
- Upcoming Q2 2020 financial results may show promising data.
- Focus on innovative treatments for significant health issues.
- None.
CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, will release its financial results for the second quarter ended June 30, 2020, before the market open on Wednesday, August 12, 2020, and host a webcast and conference call at 8:30am ET.
Wednesday, August 12th @ 8:30amET
Investors: 877-407-9716
International Investors: 201-493-6779
Conference ID: 13707708
Audio-Only Webcast: http://public.viavid.com/index.php?id=141035
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Recently published mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemm’s canal, a critical component of the conventional outflow tract. The Company’s lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (“VE-PTP”), is being developed as a potential treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema (“DME”). The Company’s third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924’s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS). For more information, please visit www.aerpio.com.
Investors & Media:
Gina Marek
VP Finance
gmarek@aerpio.com
Or
Investors:
Irina Koffler
LifeSci Advisors
ikoffler@lifesciadvisors.com
FAQ
When will Aerpio Pharmaceuticals release its Q2 2020 earnings?
What is Aerpio Pharmaceuticals' main area of focus?
What is razuprotafib?
What time is Aerpio's conference call on August 12, 2020?
